Skip to search formSkip to main contentSkip to account menu

sesamodil

Known as: 3,4-dihydro-2-(5-methoxy-2-(3-(N-methyl-N-(2-((3,4-methylenedioxy)phenoxy)ethyl)amino)propoxy)phenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine, SEMOTIADIL 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
1998
1998
To identify the binding domain of a new Ca2+ antagonist semotiadil on L-type Ca2+channels from skeletal muscle, photolabeling was… 
1995
1995
1 The aim of the present study was to determine whether antianginal efficacy of semotiadil fumarate (SD‐3211), a structurally… 
1994
1994
Summary: We assessed the binding characteristics of a benzothiazine Ca2+-channel antagonist, semotiadil, in canine skeletal… 
1992
1992
Summary: The present experiments were undertaken to elucidate Ca2+ antagonistic and binding properties of semotiadil and its (S… 
1990
1990
The effects of the novel Ca2+ antagonist sesamodil fumarate (JAN), (+)-3,4-dihydro-2-[5-methoxy-2-[3-[N-methyl-N-[2-[(3,4…